---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42312751.md"
description: "$Eli Lilly(LLY.US) rose slightly, $SBP GROUP(01177.HK) fell over one percent, and $INNOGEN-B(02591.HK) dropped eight percent. The three biopharma stocks showed divergence in Hong Kong and US markets today between GLP-1 and innovative drugs—$Eli Lilly(LLY.US) is expanding global channels for GLP-1 drugs Mounjaro/Zepbound and seeing sales ramp-up for its Alzheimer's drug; $SBP GROUP(01177.HK) is a leading Hong Kong-listed generic/innovative drug company that has completed a round of valuation repair; $INNOGEN-B(02591.HK) is a small-cap Hong Kong-listed Biotech suffering capital outflows. Is it that GLP-1 hasn't found an independent growth curve among local Hong Kong-listed manufacturers, or is the valuation pressure on Hong Kong-listed Biotech itself weighing? It looks more like the latter—small-cap stocks like $INNOGEN-B(02591.HK), without cornerstone investor lock-ups, fall the fastest."
datetime: "2026-06-30T10:54:12.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42312751.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42312751.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42312751.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
---

# $Eli Lilly(LLY.US) rose slightly, $SBP GROUP(01177…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [02591.HK](https://longbridge.com/en/quote/02591.HK.md)